S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Become an Investor in Brooklyn Gin (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Become an Investor in Brooklyn Gin (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Become an Investor in Brooklyn Gin (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Become an Investor in Brooklyn Gin (Ad)pixel
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Hot craft spirits opportunity you don't want to miss (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:URGN

UroGen Pharma - URGN Stock Forecast, Price & News

$8.40
+0.41 (+5.13%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.01
$8.67
50-Day Range
$7.55
$8.87
52-Week Range
$4.85
$12.63
Volume
138,279 shs
Average Volume
109,111 shs
Market Capitalization
$191.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

UroGen Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
114.3% Upside
$18.00 Price Target
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
1.43mentions of UroGen Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3,057 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.50) to ($3.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

230th out of 1,048 stocks

Pharmaceutical Preparations Industry

107th out of 513 stocks


URGN stock logo

About UroGen Pharma (NASDAQ:URGN) Stock

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
URGN UroGen Pharma Ltd.
Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
10 Best Immunotherapy Stocks To Buy Now
UroGen Pharma Ltd. (URGN)
UroGen Pharma Announces Label Change For JELMYTO - Quick Facts
See More Headlines
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Company Calendar

Last Earnings
11/10/2022
Today
1/26/2023
Next Earnings (Estimated)
3/20/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
195
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+114.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-110,820,000.00
Net Margins
-175.16%
Pretax Margin
-171.63%

Debt

Sales & Book Value

Annual Sales
$48.04 million

Miscellaneous

Free Float
19,830,000
Market Cap
$191.02 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Elizabeth BarrettElizabeth Barrett
    President, Chief Executive Officer & Director
  • Dong Kim
    Chief Financial & Accounting Officer
  • Marina Konorty
    EVP-Research & Development & Technical Operations
  • Mark P. SchoenbergMark P. Schoenberg
    Chief Medical Officer
  • Moran Mieron
    Director-Research & Pre-Clinical Affairs













URGN Stock - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings
or view top-rated stocks.

What is UroGen Pharma's stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price objectives for UroGen Pharma's shares. Their URGN share price forecasts range from $11.00 to $23.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 114.3% from the stock's current price.
View analysts price targets for URGN
or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2023?

UroGen Pharma's stock was trading at $8.87 at the start of the year. Since then, URGN shares have decreased by 5.3% and is now trading at $8.40.
View the best growth stocks for 2023 here
.

Are investors shorting UroGen Pharma?

UroGen Pharma saw a decrease in short interest in January. As of January 15th, there was short interest totaling 569,600 shares, a decrease of 15.2% from the December 31st total of 671,700 shares. Based on an average daily trading volume, of 73,500 shares, the days-to-cover ratio is presently 7.7 days. Approximately 2.9% of the company's stock are sold short.
View UroGen Pharma's Short Interest
.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 20th 2023.
View our URGN earnings forecast
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) posted its quarterly earnings data on Thursday, November, 10th. The company reported ($1.13) earnings per share for the quarter, topping analysts' consensus estimates of ($1.22) by $0.09. The company earned $16.10 million during the quarter, compared to analyst estimates of $20.30 million.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.87%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends
.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $8.40.

How much money does UroGen Pharma make?

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $191.02 million and generates $48.04 million in revenue each year. The company earns $-110,820,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis.

How many employees does UroGen Pharma have?

The company employs 195 workers across the globe.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.

This page (NASDAQ:URGN) was last updated on 1/27/2023 by MarketBeat.com Staff